
Nora Ruel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4593550/publications.pdf Version: 2024-02-01



NORA RUE

#	Article	IF	CITATIONS
1	Comparison of Reduced-Intensity and Conventional Myeloablative Regimens for Allogeneic Transplantation in Non-Hodgkin's Lymphoma. Biology of Blood and Marrow Transplantation, 2006, 12, 1326-1334.	2.0	98
2	Wireless Monitoring Program of Patient-Centered Outcomes and Recovery Before and After Major Abdominal Cancer Surgery. JAMA Surgery, 2017, 152, 852.	4.3	77
3	Pooled Analysis of Clinical Outcomes with Neoadjuvant Cisplatin and Gemcitabine Chemotherapy for Muscle Invasive Bladder Cancer. Journal of Urology, 2013, 189, 1682-1686.	0.4	68
4	A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica, 2015, 100, 357-362.	3.5	66
5	Complications and outcomes of salvage robotâ€assisted radical prostatectomy: a singleâ€institution experience. BJU International, 2014, 113, 769-776.	2.5	63
6	Radiation History Affects Continence Outcomes After AdVance Transobturator Sling Placement in Patients With Post-prostatectomy Incontinence. Urology, 2013, 82, 713-717.	1.0	51
7	Pilot study of a telehealth perioperative physical activity intervention for older adults with cancer and their caregivers. Supportive Care in Cancer, 2020, 28, 3867-3876.	2.2	40
8	Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention. European Journal of Oncology Nursing, 2017, 29, 125-134.	2.1	39
9	Analysis of regional lymph nodes in periprostatic fat following robotâ€assisted radical prostatectomy. BJU International, 2012, 109, 603-607.	2.5	33
10	A Multimedia Self-management Intervention to Prepare Cancer Patients and Family Caregivers for Lung Surgery and Postoperative Recovery. Clinical Lung Cancer, 2017, 18, e151-e159.	2.6	32
11	Prospective randomised nonâ€inferiority trial of pelvic drain placement vs no pelvic drain placement after robotâ€assisted radical prostatectomy. BJU International, 2018, 121, 357-364.	2.5	31
12	Stereotactic Body Radiation Therapy to the Prostate Bed: Results of a Phase 1 Dose-Escalation Trial. International Journal of Radiation Oncology Biology Physics, 2020, 106, 537-545.	0.8	28
13	Lymph Node Fluorescence During Robot-Assisted Radical Prostatectomy With Indocyanine Green: Prospective Dosing Analysis. Clinical Genitourinary Cancer, 2017, 15, e529-e534.	1.9	25
14	A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 116-122.	1.6	24
15	Improving Palliative Care and Quality of Life in Pancreatic Cancer Patients. Journal of Palliative Medicine, 2022, 25, 720-727.	1.1	22
16	Effect of Alvimopan on Return of Bowel Function After Robot-Assisted Radical Cystectomy. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2014, 24, 693-697.	1.0	21
17	Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma. , 2021, 9, e002009.		21
18	The Effect of Nerve-Sparing Robot-Assisted Radical Cystoprostatectomy on Erectile Function in a Preoperatively Potent Population. Journal of Endourology, 2014, 28, 1352-1356.	2.1	18

Nora Ruel

#	Article	IF	CITATIONS
19	Critical Analysis of Hospital Readmission and Cost Burden After Robot-Assisted Radical Cystectomy. Journal of Endourology, 2016, 30, 83-91.	2.1	18
20	Phase II trial of XL184 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy: A California Cancer Consortium phase II trial (NCI 9303) Journal of Clinical Oncology, 2014, 32, 8014-8014.	1.6	18
21	Improving family caregiver and patient outcomes in lung cancer surgery: Study protocol for a randomized trial of the multimedia self-management (MSM) intervention. Contemporary Clinical Trials, 2019, 83, 88-96.	1.8	16
22	Clinical and Translational Assessment of VEGFR1 as a Mediator of the Premetastatic Niche in High-Risk Localized Prostate Cancer. Molecular Cancer Therapeutics, 2015, 14, 2896-2900.	4.1	15
23	Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer. Prostate International, 2019, 7, 102-107.	2.3	15
24	Pilot study of an interdisciplinary supportive care planning intervention in pancreatic cancer. Supportive Care in Cancer, 2016, 24, 3417-3424.	2.2	13
25	Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance. Oncotarget, 2018, 9, 21359-21365.	1.8	12
26	Oncologic outcomes in men with metastasis to the prostatic anterior fat pad lymph nodes: a multi-institution international study. BMC Urology, 2015, 15, 79.	1.4	10
27	Prognostic Significance of Neutrophilic Infiltration in Benign Lymph Nodes in Patients with Muscle-invasive Bladder Cancer. European Urology Focus, 2017, 3, 130-135.	3.1	9
28	Integration of a Palliative Care Intervention into Community Practice for Lung Cancer: A Study Protocol and Lessons Learned with Implementation. Journal of Palliative Medicine, 2017, 20, 1327-1337.	1.1	9
29	Translation and Evaluation of a Lung Cancer, Palliative Care Intervention for Community Practice. Journal of Pain and Symptom Management, 2018, 56, 709-718.	1.2	9
30	Risk of complications and urinary incontinence following cytoreductive prostatectomy: a multi-institutional study. Asian Journal of Andrology, 2018, 20, 9.	1.6	9
31	Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma. Oncology, 2016, 90, 307-312.	1.9	8
32	A nurse-led intervention for fear of cancer progression in advanced cancer: A pilot feasibility study. European Journal of Oncology Nursing, 2020, 49, 101855.	2.1	8
33	Outcomes and toxicity of 313 prostate cancer patients receiving helical tomotherapy after radical prostatectomy. Advances in Radiation Oncology, 2017, 2, 597-607.	1.2	7
34	Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials. JNCI Cancer Spectrum, 2020, 4, pkaa067.	2.9	7
35	CKD-EPI and Cockcroft-Gault Equations Identify Similar Candidates for Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer. PLoS ONE, 2014, 9, e94471.	2.5	7
36	Lymph node-positive prostate cancer after robotic prostatectomy and extended pelvic lymphadenectomy. Journal of Robotic Surgery, 2018, 12, 425-431.	1.8	6

Nora Ruel

#	Article	IF	CITATIONS
37	Quality of Life, Symptoms, and Self-Management Strategies After Gastroesophageal Cancer Surgery. Journal of Pain and Symptom Management, 2018, 56, e4-e8.	1.2	6
38	Preoperative Androgen Deprivation Therapy for Localized Prostate Cancer: Delayed Biochemical Recurrence in High-Risk Disease. Clinical Genitourinary Cancer, 2014, 12, 149-154.	1.9	5
39	NCl–Clinical Trial Accrual in a Community Network Affiliated with a Designated Cancer Center. Journal of Clinical Medicine, 2020, 9, 1970.	2.4	4
40	Readmission and complications after robotic surgery: experience of 10,000 operations at a comprehensive cancer center. Journal of Robotic Surgery, 2021, 15, 37-44.	1.8	3
41	Prostate Cancer Characteristics and Outcomes after Prostatectomy in Asian-American Men. Clinical Genitourinary Cancer, 2022, 20, 92-92.e6.	1.9	2
42	Complications Based on Prostate Size After Plasmakinetic Enucleation of the Prostate. Journal of Endourology, 2022, , .	2.1	2
43	Multiâ€institutional review of nonâ€hypospadiac penile urethral stricture management and outcomes. International Journal of Urology, 2022, 29, 376-382.	1.0	2
44	Race/Ethnicity and Survival in Metastatic Renal Cell Carcinoma: Outcomes for Patients Receiving First Line Targeted Therapies. Kidney Cancer, 2020, 4, 159-166.	0.4	1
45	NCI #8412: A randomized phase II trial of AZD6244 alone and AZD6244 plus temsirolimus for soft-tissue sarcomas Journal of Clinical Oncology, 2014, 32, 10526-10526.	1.6	1
46	Family Caregiver Preparedness: Developing an Educational Intervention for Symptom Management. Clinical Journal of Oncology Nursing, 2022, 26, 165-175.	0.6	1
47	Assessment of time from cytoreductive nephrectomy (CN) to initiation of targeted therapy (TT) in patients with metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2014, 32, 540-540.	1.6	0
48	NCI 8628: A randomized phase II study of ziv-aflibercept (Z) and high-dose interleukin-2 (HD IL-2) or HD IL-2 alone for inoperable stage III or IV melanoma—Efficacy and biomarker study Journal of Clinical Oncology, 2014, 32, TPS9120-TPS9120.	1.6	0
49	Assessment of time from cytoreductive nephrectomy (CN) to initiation of targeted therapy (TT) in patients with metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2014, 32, e15614-e15614.	1.6	0